Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lifecore Biomedical, Inc. \De\ (LFCR) Cash from Restructuring (2020 - 2023)

Lifecore Biomedical, Inc. \De\ (LFCR) has 4 years of Cash from Restructuring data on record, last reported at -$38.4 million in Q2 2023.

  • For Q2 2023, Cash from Restructuring changed N/A year-over-year to -$38.4 million; the TTM value through May 2023 reached -$17.2 million, changed N/A, while the annual FY2024 figure was $1.4 million, 119.06% up from the prior year.
  • Cash from Restructuring reached -$38.4 million in Q2 2023 per LFCR's latest filing, down from $2.6 million in the prior quarter.
  • Across five years, Cash from Restructuring topped out at $34.9 million in Q2 2021 and bottomed at -$38.4 million in Q2 2023.
  • Average Cash from Restructuring over 4 years is $3.9 million, with a median of $3.9 million recorded in 2022.
  • Peak YoY movement for Cash from Restructuring: crashed 101.53% in 2021, then skyrocketed 154.8% in 2022.
  • A 4-year view of Cash from Restructuring shows it stood at $6.0 million in 2020, then plummeted by 101.53% to -$92000.0 in 2021, then soared by 20369.57% to $18.6 million in 2022, then plummeted by 305.91% to -$38.4 million in 2023.
  • Per Business Quant database, its latest 3 readings for Cash from Restructuring were -$38.4 million in Q2 2023, $2.6 million in Q1 2023, and $18.6 million in Q4 2022.